HPV infections in transgender people: a hidden health gap gets a closer look

NCT ID NCT05981807

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This observational study measures how often HPV infections and other sexually transmitted infections occur in transgender adults. Researchers will check for HPV at genital, anal, and oral sites, and also look for anal dysplasia, which can be a precursor to cancer. The study includes 200 transgender people aged 18 and older who have not been vaccinated against HPV. The goal is to understand infection rates overall and by HIV status, which may help shape future screening and prevention efforts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study succeeds, it could reveal how common HPV infections are in transgender people, guiding better screening and prevention strategies for this group.
What could go wrong
This is an observational study, so it cannot test treatments. The findings may not apply to all transgender people, and the study does not follow participants over time to see how infections change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Oct 2024

Finished

Jun 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include people who belong to the transgender population : i.e. people who do not identify to the gender assigned at birth (man to woman and woman to man).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Age ≥ 18 years * To belong to transgender population : i.e. people who doesn't identify to the gender assigned at birth * To be affiliated to a social security system or be beneficiary of AME Exclusion criteria: * To have ever been vaccinated against HPV * Research participation refusal * People under guardianship or curatorship, or deprived of liberty by administrative or judiciary measure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human immunodeficiency virus infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bichat Hospital

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.